RxDoctor Payments Data

Sarah Garner, MD

Internal Medicine · Des Moines, IANPI 1700089539

Payments from drug & device makers

$204in general payments, 2019–2025

Across 12 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$57
  • Acadia Pharmaceuticals Inc$41
  • Gilead$17
  • Lexicon Pharmaceuticals, Inc.$17
  • Novo Nordisk$15
  • Boehringer Ingelheim$15
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$18993%
  • Education$157%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$204 in reported general payments places this provider in the 60th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$307,525
Medicare patients
577
Services billed
14,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$201,798
MounjaroTirzepatide152$182,127
EliquisApixaban199$147,568
VumerityDiroximel Fumarate12$104,227
JardianceEmpagliflozin109$96,157
Enbrel SureclickEtanercept12$88,490
JanuviaSitagliptin Phosphate73$78,006
XareltoRivaroxaban76$55,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$48,334
XifaxanRifaximin12$39,412
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$34,900
OxycontinOxycodone Hcl28$32,366
Tresiba Flextouch U-200Insulin Degludec23$28,161
TivicayDolutegravir Sodium11$27,380
TrulicityDulaglutide26$24,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$15$221,372169 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$15$124,541150 claims
AbbVieViberzi, Linzess$13$27,39429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →